A detailed history of Yousif Capital Management, LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Yousif Capital Management, LLC holds 18,505 shares of PCRX stock, worth $315,140. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,505
Previous 18,940 2.3%
Holding current value
$315,140
Previous $541,000 48.61%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$11.7 - $28.46 $5,089 - $12,380
-435 Reduced 2.3%
18,505 $278,000
Q2 2024

Jul 31, 2024

SELL
$25.5 - $31.51 $53,677 - $66,328
-2,105 Reduced 10.0%
18,940 $541,000
Q1 2024

Apr 26, 2024

SELL
$27.7 - $35.48 $59,555 - $76,282
-2,150 Reduced 9.27%
21,045 $614,000
Q4 2023

Feb 01, 2024

SELL
$26.32 - $34.31 $14,870 - $19,385
-565 Reduced 2.38%
23,195 $782,000
Q3 2023

Oct 30, 2023

SELL
$30.68 - $40.09 $41,172 - $53,800
-1,342 Reduced 5.35%
23,760 $728,000
Q2 2023

Aug 02, 2023

SELL
$36.12 - $47.5 $56,997 - $74,955
-1,578 Reduced 5.91%
25,102 $1.01 Million
Q1 2023

May 02, 2023

SELL
$35.53 - $43.38 $119,913 - $146,407
-3,375 Reduced 11.23%
26,680 $1.09 Million
Q4 2022

Jan 09, 2023

SELL
$38.19 - $57.45 $267,139 - $401,862
-6,995 Reduced 18.88%
30,055 $0
Q3 2022

Nov 04, 2022

SELL
$51.24 - $58.89 $15,833 - $18,197
-309 Reduced 0.83%
37,050 $1.97 Million
Q2 2022

Aug 01, 2022

SELL
$51.49 - $81.64 $175,580 - $278,392
-3,410 Reduced 8.36%
37,359 $2.18 Million
Q1 2022

May 12, 2022

BUY
$60.03 - $76.49 $51,925 - $66,163
865 Added 2.17%
40,769 $3.11 Million
Q4 2021

Jan 31, 2022

BUY
$47.97 - $62.21 $1.91 Million - $2.48 Million
39,904 New
39,904 $2.4 Million

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $780M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Yousif Capital Management, LLC Portfolio

Follow Yousif Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Yousif Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Yousif Capital Management, LLC with notifications on news.